Oligomerix is a clinical-stage biotechnology company developing oral small-molecule inhibitors of tau self-association aimed at Alzheimer’s disease and rare tauopathies. Its lead candidate inhibits the beginning of the tau aggregation cascade and has shown efficacy in animal models; preclinical safety studies are complete. The company plans Phase 1a clinical studies to begin in early 3Q 2022 and will use the recent funding to accelerate that transition. A portion of the Series B extension will fund early characterization of multiple second-generation asset series focused on disease modification in dementia. Historically, Oligomerix financed development through non-dilutive NIH-sponsored grants and other small rounds to complete preclinical testing. The company is seeking strategic partners and additional investors to support continued clinical development. Oligomerix focuses on developing disease‑modifying therapeutics for Alzheimer’s disease and related neurodegenerative disorders. The company concentrates on small molecule inhibitors, immunotherapeutic approaches and biomarkers that target tau oligomers and their recently discovered proteolytic enzymatic activity. It intends to use recently raised funds to advance its small molecule inhibitor programs. Oligomerix is led by president and CEO James Moe, Ph.D., MBA, and was founded in 2006. The company is based in New York, located within the Audubon Biomedical Science and Technology Park at Columbia University Medical Center. Its current financing activity includes a completed Series B round. Oligomerix develops disease-modifying therapeutics for Alzheimer’s disease and related neurodegenerative disorders. The company focuses on small molecule inhibitors, immunotherapeutic approaches and biomarkers that target tau oligomers and a newly discovered proteolytic enzymatic activity. It is developing a compound-screening assay to identify disease-modifying small molecules and antibody-based therapeutics directed at tau oligomers and their proteolytic activity. Oligomerix intends to use the capital from its recent financing to advance its tau protease inhibitor program, which aims to neutralize tau outside of neurons. Founded in 2006 and led by president and CEO James Moe, Ph.D., MBA, and CSO Eliot Davidowitz, Ph.D., the company is located in the Audubon Biomedical Science and Technology Park at Columbia University Medical Center. The company completed approximately $2M in Series A financing in which new convertible preferred shares were issued and debt was converted.

Total raised

$8M

Funding rounds

3

Latest round

Series B

Latest activity

Jun 2022